Drug Profile
Balsalazide - Salix Pharmaceuticals
Alternative Names: Ao Rui Xin; Balacol; Balsalazide disodium; Balsalazine; Balzide; Basazyde; Benoquin; BX 661A; Colazal; Colazid; Colazide; Giazo; PremidLatest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Biorex Laboratories
- Developer Pharmatel; Salix Pharmaceuticals; Takeda; Teva Pharmaceutical Industries
- Class Anti-inflammatories; Irritable bowel syndrome therapies; Salicylates; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ulcerative colitis
- Discontinued Cancer; Radiation injuries
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 21 Apr 2017 No recent reports on development identified - Registered for Ulcerative colitis in New Zealand (PO)
- 07 Apr 2015 Launched for Ulcerative colitis in China, Philippines, Taiwan, Singapore, Thailand, Myanmar, Malaysia, Hong Kong, Indonesia, United Arab Emirates and India (PO) before April 2015